AcelRx Pharmaceuticals Inc  

(Public, NASDAQ:ACRX)   Watch this stock  
Find more results for ACRX
3.92
+0.06 (1.55%)
After Hours: 3.94 +0.02 (0.51%)
Apr 1, 5:45PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.69 - 3.94
52 week 3.58 - 12.35
Open 3.94
Vol / Avg. 657,165.00/961,861.00
Mkt cap 168.74M
P/E     -
Div/yield     -
EPS -0.77
Shares 43.71M
Beta 2.07
Inst. own 82%
May 6, 2015
Q1 2015 AcelRx Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
AcelRx Pharmaceuticals Inc at ROTH Conference
Mar 9, 2015
Q4 2014 AcelRx Pharmaceuticals Inc Earnings Call
Mar 9, 2015
Q4 2014 AcelRx Pharmaceuticals Inc Earnings Release
Mar 2, 2015
AcelRx Pharmaceuticals Inc at Cowen Health Care Conference
Feb 24, 2015
AcelRx Pharmaceuticals Inc at RBC Healthcare Conference
Feb 9, 2015
AcelRx Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -6114.16% -639.31%
Operating margin -5211.95% -721.66%
EBITD margin - -705.06%
Return on average assets -60.61% -33.95%
Return on average equity -104.84% -55.67%
Employees 50 -
CDP Score - -

Address

351 Galveston Drive
REDWOOD CITY, CA 94063
United States - Map
+1-650-2163500 (Phone)
+1-650-2166500 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AcelRx Pharmaceuticals, Inc. is a development-stage company. It is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company�s lead product candidate, Zalviso, formerly Sufentanil NanoTab PCA System (ARX-01), is under review by the Food and Drug Administration (FDA) for marketing approval, and is designed to improve the management of moderate-to-severe acute pain in patients in the hospital setting. The Company has three additional product candidates in clinical development: ARX-02 for the treatment of cancer breakthrough pain; ARX-03 for providing mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician�s office; and ARX-04, a non-invasive, fast-onset sublingual product for the treatment of moderate-to-severe acute pain.

Officers and directors

Adrian Adams Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Richard A. King President, Director
Age: 49
Bio & Compensation  - Reuters
Timothy E. Morris Chief Financial Officer, Principal Accounting Officer
Age: 53
Bio & Compensation  - Reuters
Pamela P. Palmer M.D. Ph.D. Chief Medical Officer, Director
Age: 51
Bio & Compensation  - Reuters
Badri N. Dasu Chief Engineering Officer
Age: 50
Bio & Compensation  - Reuters
Lawrence G. Hamel Chief Development Officer
Age: 62
Bio & Compensation  - Reuters
Richard F. Afable M.D. Director
Age: 60
Bio & Compensation  - Reuters
Mark G. Edwards Independent Director
Age: 56
Bio & Compensation  - Reuters
Stephen J. Hoffman M.D. Ph.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Howard B. Rosen Interim Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters